Skip to main content
Skip to main content
ITGR logo

Integer Holdings Corporation (ITGR)

$93.40 $-1.74 (-1.83%) |Strong · 66
Bottom line: BUY — our Council read (66/100) and AI Score (66/100) broadly agree.
MCap: $3.17B| P/E Ratio: 22.4| Vol: 494.4K| Target: $101.00 (+8.1%)|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Integer Holdings Corporation (ITGR) trades at $93.40 with AI Score 66/100 (Grade B+). Integer Holdings Corporation is a medical device outsource manufacturer, providing products and services to multi-national original equipment manufacturers. Market cap: $3.17B, Sector: Healthcare.

Price live · AI analysis from May 9, 2026
Integer Holdings Corporation is a medical device outsource manufacturer, providing products and services to multi-national original equipment manufacturers. The company operates through medical and non-medical segments, serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical markets.

ITGR stock analysis for 2026: Analysts have set a consensus price target of $101.00 for Integer Holdings Corporation, suggesting 8.1% upside from the current price of $93.40. The AI MoonshotScore is 66/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
BUY 66/100 · B+

ITGR: 1/1 perspectives are bullish.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

Integer Holdings Corporation (ITGR) Healthcare & Pipeline Overview

CEOPayman Khales
Employees11000
HeadquartersPlano, TX, US
IPO Year2000

Integer Holdings Corporation, a medical device outsource manufacturer, serves multi-national original equipment manufacturers in the cardiac, neuromodulation, orthopedics, and vascular markets. With a focus on both medical and non-medical segments, the company provides a range of products, including implantable devices, batteries, and surgical components, maintaining a P/E ratio of 22.4.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 9, 2026

What Is the Investment Thesis for ITGR?

Integer Holdings Corporation presents a compelling investment case based on its established position as a medical device outsource manufacturer. The company's diverse product portfolio, serving multiple high-growth medical sectors, offers revenue stability and expansion opportunities. With a P/E ratio of 22.4 and a profit margin of 7.7%, Integer demonstrates financial health. Key growth catalysts include expanding its presence in the neuromodulation and orthopedics markets. However, potential risks include increasing competition and regulatory changes in the medical device industry. The company's beta of 0.71 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

ITGR Key Highlights

  • Market capitalization of $3.17B, reflecting substantial investor confidence in the company's market position and growth prospects.
  • P/E ratio of 22.4, indicating a reasonable valuation relative to earnings compared to the broader healthcare sector.
  • Profit margin of 7.7%, showcasing the company's ability to generate profits from its revenue streams.
  • Gross margin of 23.3%, reflecting the efficiency of Integer's manufacturing and supply chain operations.
  • Beta of 0.71, suggesting lower volatility compared to the overall market, making it a potentially stable investment.

Who Are ITGR's Competitors?

ITGR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
CON Concentra Group Holdings Parent, Inc. $31.98 +0.20% $4.09B 87
DCTH Delcath Systems, Inc. $13.61 +3.11% $469.84M 73
PYNKF Perimeter Medical Imaging AI, Inc. $0.20 +3.40% $18.68M 73
SSII SS Innovations International, Inc. $3.76 -0.53% $752.49M 72
RSHUF Respiri Limited $0.06 +0.00% $91.52M 68
BWAY BrainsWay Ltd. $16.02 +5.46% $628.35M 66
DMTRF 3-D Matrix, Ltd. $2.50 +11.11% $300.53M 66
CNVIF Conavi Medical Corp. $0.18 +0.00% $15.36M 66

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ITGR's Key Strengths?

  • Diverse product portfolio serving multiple medical sectors.
  • Established relationships with multi-national original equipment manufacturers.
  • Specialized manufacturing capabilities in medical devices and battery technology.
  • Global presence with manufacturing facilities in multiple countries.

What Are ITGR's Weaknesses?

  • Reliance on a limited number of key customers.
  • Exposure to regulatory changes in the medical device industry.
  • Potential for product liability claims.
  • Dependence on third-party suppliers for raw materials and components.

What Could Drive ITGR Stock Higher?

  • New product launches in the neuromodulation and orthopedics markets expected in late 2026.
  • Increasing demand for medical device outsourcing due to cost pressures on OEMs.
  • Expansion of manufacturing facilities in emerging markets to support geographic growth.

What Are the Key Risks for ITGR?

  • Regulatory changes in the medical device industry could increase compliance costs.
  • Economic downturns could reduce healthcare spending and demand for medical devices.
  • Competition from other medical device manufacturers could erode market share.
  • Product liability claims could result in significant financial losses.

What Are the Growth Opportunities for ITGR?

  • Growth opportunity 1: Expansion in Neuromodulation: Integer can capitalize on the growing neuromodulation market, projected to reach $13.3 billion by 2027. By developing and manufacturing advanced neuromodulation devices, such as spinal cord stimulators and deep brain stimulators, Integer can increase its market share. This expansion requires strategic partnerships with neuromodulation device companies and investments in research and development to create innovative products.
  • Growth opportunity 2: Penetration of the Orthopedics Market: The global orthopedics market is expected to reach $52.5 billion by 2028. Integer can increase its presence in this market by offering a wider range of orthopedic instruments and implants. This includes instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Strategic acquisitions of specialized orthopedic component manufacturers could accelerate this growth.
  • Growth opportunity 3: Advanced Surgical Device Manufacturing: The advanced surgical device market is experiencing rapid growth, driven by demand for minimally invasive surgical techniques. Integer can expand its offerings in this area by manufacturing harmonic scalpels, shaver blades, burr shavers, and radio frequency probes. Investing in advanced manufacturing technologies, such as robotic assembly and 3D printing, will be crucial for maintaining a competitive edge.
  • Growth opportunity 4: Customized Battery Solutions for Medical Devices: The market for medical device batteries is growing due to the increasing use of portable and implantable medical devices. Integer can leverage its expertise in battery technology to provide customized battery power and power management systems for medical device manufacturers. This includes rechargeable batteries, non-rechargeable batteries, and chargers. Focusing on high-performance and long-lasting battery solutions will be key.
  • Growth opportunity 5: Geographic Expansion in Emerging Markets: Emerging markets, such as China and India, are experiencing rapid growth in healthcare spending. Integer can expand its presence in these markets by establishing manufacturing facilities and distribution networks. This geographic expansion will require adapting its product offerings to meet the specific needs of these markets and navigating local regulatory requirements.

What Opportunities Does ITGR Have?

  • Expansion in emerging markets, such as China and India.
  • Development of new products and technologies.
  • Strategic acquisitions of complementary businesses.
  • Increased outsourcing of medical device manufacturing.

What Threats Does ITGR Face?

  • Increasing competition from other medical device manufacturers.
  • Economic downturns affecting healthcare spending.
  • Technological obsolescence.
  • Fluctuations in currency exchange rates.

What Are ITGR's Competitive Advantages?

  • Established relationships with multi-national original equipment manufacturers.
  • Specialized manufacturing capabilities in medical devices and battery technology.
  • Diverse product portfolio serving multiple high-growth medical sectors.
  • Global presence with manufacturing facilities in multiple countries.

What Does ITGR Do?

Founded in 1970 and headquartered in Plano, Texas, Integer Holdings Corporation operates as a medical device outsource manufacturer, serving the United States, Puerto Rico, Costa Rica, and international markets. The company functions through two primary segments: Medical and Non-Medical. Integer provides a diverse array of products used in interventional cardiology, structural heart procedures, heart failure treatments, peripheral vascular interventions, neurovascular procedures, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Integer's offerings include cardiac rhythm management products like implantable pacemakers and defibrillators, neuromodulation products such as spinal cord stimulators, and a variety of batteries, feedthroughs, device enclosures, and machined components. The company also supplies arthroscopic, laparoscopic, and general surgery devices, along with orthopedic products and customized battery power solutions. Integer serves multi-national original equipment manufacturers and their subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical markets. Integer has a market capitalization of $3.17B and employs approximately 11,000 people.

What Products and Services Does ITGR Offer?

  • Manufactures medical devices for interventional cardiology.
  • Provides products for structural heart procedures.
  • Offers solutions for heart failure management.
  • Manufactures devices for peripheral vascular interventions.
  • Provides products for neuromodulation, including spinal cord stimulators.
  • Offers orthopedic products, including surgical instruments.
  • Manufactures customized battery power and power management systems.
  • Provides medical technologies for various applications.

How Does ITGR Make Money?

  • Outsource manufacturing of medical devices for original equipment manufacturers (OEMs).
  • Provides products and services to both medical and non-medical segments.
  • Customized battery power and power management systems for various markets.
  • Serves multi-national corporations and their subsidiaries.

What Industry Does ITGR Operate In?

Integer Holdings Corporation operates within the medical device industry, a sector characterized by continuous innovation and increasing demand due to an aging global population and advancements in medical technology. The market is competitive, with companies vying for contracts with original equipment manufacturers. Trends include a growing emphasis on minimally invasive procedures and the development of smart medical devices. Integer's focus on outsourcing positions it to capitalize on the increasing need for specialized manufacturing capabilities within the medical device industry. The company competes with CON: Concentra Group Holdings Parent, Inc. and other specialized manufacturers.

Who Are ITGR's Key Customers?

  • Multi-national original equipment manufacturers (OEMs) in the medical device industry.
  • Affiliated subsidiaries of these OEMs.
  • Companies in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical markets.
  • Customers in the portable medical market.
AI Confidence: 68% Updated: May 9, 2026

Integer Holdings Corporation (ITGR) Valuation Context

Valued at $3.17B, ITGR is classified as a mid-cap stock. Relative to its peer group, ITGR's quantitative score of 66/100 is roughly in line with the peer average of 75/100.

ROE 8%Key Financial Metrics

Return on equity for Integer Holdings Corporation stands at 8.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.2%, showing how much profit it generates from its asset base. ITGR trades at a trailing price-to-earnings ratio of 22.39, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Integer Holdings Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.48 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project Integer Holdings Corporation revenue of about $1.82B for fiscal 2026, with EPS near $6.08. The estimate reflects 7 contributing analysts.

ITGR Financials

Fundamental Snapshot

Revenue Growth (FY)
+7.6%
Net Income Growth (FY)
-14.3%
EPS Growth (FY)
-17.8%
Free Cash Flow Growth (FY)
+5.3%
P/E (TTM)
22.6
Return on Equity (TTM)
+8.2%
Current Ratio
3.8
EV/EBITDA (TTM)
13.7

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying indicates confidence in the company's future prospects, suggesting that leadership believes in their strategic direction.
  • Positive community sentiment has emerged around Integer's innovative medical technology solutions, driving enthusiasm among investors.
  • The company's focus on expanding its product offerings in the medical device sector has garnered attention, reflecting strong growth potential.
  • Recent partnerships and collaborations in the healthcare space have positioned Integer favorably, enhancing its market reputation.

Bear Case

  • Some analysts express concerns over potential supply chain disruptions that could impact production timelines and delivery capabilities.
  • Community discussions reveal skepticism regarding Integer's ability to maintain competitive advantages in a rapidly evolving market.
  • Recent earnings reports showed mixed results, leading to doubts about the company's operational efficiency and future profitability.
  • Increased competition in the medical device industry raises concerns about market share erosion and pricing pressures.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026

ITGR Latest News

ITGR Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ITGR.

Price Targets

Consensus target: $101.00

ITGR MoonshotScore

66/100

What does this score mean?

The MoonshotScore rates ITGR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Latest Integer Holdings Corporation Analysis

Leadership: Payman Khales

CEO

Payman Khales serves as the CEO of Integer Holdings Corporation, bringing extensive experience in the medical device and technology sectors. Prior to Integer, Khales held leadership positions at various global companies, focusing on strategic growth and operational excellence. His background includes a strong emphasis on innovation, customer-centric solutions, and driving shareholder value. Khales's expertise spans across multiple disciplines, including engineering, product development, and commercial operations, making him well-suited to lead Integer's diverse business segments.

Track Record: Since assuming the role of CEO, Payman Khales has focused on expanding Integer's presence in key markets and enhancing its manufacturing capabilities. Key achievements include strategic partnerships with leading medical device companies and investments in advanced technologies. Under his leadership, Integer has maintained a strong financial performance and continued to innovate in the medical device outsourcing space.

ITGR Healthcare Stock FAQ

What does Integer Holdings Corporation do?

Integer Holdings Corporation is a medical device outsource manufacturer that provides products and services to multi-national original equipment manufacturers (OEMs) in the medical device industry. The company operates through medical and non-medical segments, offering a wide range of products, including implantable devices, batteries, and surgical components. Integer serves the cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical markets, providing customized solutions to meet the specific needs of its customers. Its business model focuses on providing high-quality manufacturing and engineering services to help OEMs bring innovative medical devices to market.

What do analysts say about ITGR stock?

Analyst consensus on Integer Holdings Corporation (ITGR) reflects a cautiously optimistic outlook. Key valuation metrics, such as the P/E ratio of 22.4, suggest a reasonable valuation compared to peers in the healthcare sector. Growth considerations include the company's expansion in high-growth markets, such as neuromodulation and orthopedics, and its ability to maintain strong relationships with key customers. Analysts also note potential risks, such as regulatory changes and increasing competition, which could impact the company's financial performance. The company's beta of 0.71 suggests lower volatility compared to the overall market.

What are the main risks for ITGR?

Integer Holdings Corporation faces several key risks inherent to the medical device industry. Regulatory changes, such as stricter approval processes or new compliance requirements, could increase costs and delay product launches. Economic downturns could reduce healthcare spending, impacting demand for medical devices. Increasing competition from other manufacturers could erode market share and pricing power. Product liability claims pose a significant financial risk, particularly in the event of device malfunctions or patient injuries. Additionally, the company's reliance on a limited number of key customers could create vulnerability if those relationships are disrupted.

What are the key factors to evaluate for ITGR?

Integer Holdings Corporation (ITGR) holds an AI score of 66/100 (moderate). P/E: 22.4x vs the S&P 500's ~20-25x. Analysts target $101.00 (+8%). Not financial advice.

How frequently does ITGR data refresh on this page?

ITGR prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven ITGR's recent stock price performance?

Integer Holdings Corporation (ITGR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio serving multiple medical sectors. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ITGR overvalued or undervalued right now?

Integer Holdings Corporation (ITGR) trades at 22.4x earnings. Analysts target $101.00 (+8%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying ITGR?

Before investing in Integer Holdings Corporation (ITGR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
Data Sources

Popular Stocks